Generic Ubrelvy Availability
Last updated on Apr 10, 2025.
Ubrelvy is a brand name of ubrogepant, approved by the FDA in the following formulation(s):
UBRELVY (ubrogepant - tablet;oral)
Is there a generic version of Ubrelvy available?
No. There is currently no therapeutically equivalent version of Ubrelvy available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ubrelvy. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Tablet formulation for CGRP active compounds
Patent 10,117,836
Issued: November 6, 2018
Inventor(s): Johnson Mary Ann & Allain Leonardo Resende & Eickhoff W. Mark & Ikeda Craig B. & Brown Chad D. & Flanagan & Jr. Francis J. & Nofsinger Rebecca & Marota Melanie & Lupton Lisa & Patel Paresh B. & Xi Hanmi & Xu Wei
Assignee(s): Merck Sharp & Dohme Corp.The present invention is directed to compositions comprising an extrudate or solid solution of a compound, or a salt thereof, of Formula I (API): Formula I, wherein “R” is independently H or —F, in a water-soluble polymer matrix which further comprises a disintegration system allowing a tablet made therefrom to rapidly disintegrate in the environment in which the API is to be released.
Patent expiration dates:
- January 30, 2035✓
- January 30, 2035
-
Treatment of migraine
Patent 11,717,515
Issued: August 8, 2023
Inventor(s): Trugman; Joel et al.
Assignee(s): Allergan Pharmaceuticals International Limited (Dublin, IE)The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors.
Patent expiration dates:
- December 22, 2041✓
- December 22, 2041
-
Treatment of migraine
Patent 11,857,542
Issued: January 2, 2024
Inventor(s): Trugman; Joel M. et al.
Assignee(s): Allergan Pharmaceuticals International Limited (Dublin, IE)The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors.
Patent expiration dates:
- December 22, 2041✓
- December 22, 2041
-
Tablet formulation for CGRP active compounds
Patent 11,925,709
Issued: March 12, 2024
Inventor(s): Johnson; Mary Ann et al.
Assignee(s): Merck Sharp & Dohme Corp. (Rahway, NJ)The present invention is directed to compositions comprising an extrudate or solid solution of a compound, or a salt thereof, of Formula I (API): ##STR00001##
wherein “R.sup.a” is independently —H or —F, in a water-soluble polymer matrix which further comprises a disintegration system allowing a tablet made therefrom to rapidly disintegrate in the environment in which the API is to be released.Patent expiration dates:
- January 30, 2035✓
- January 30, 2035
-
Treatment of migraine
Patent 12,070,450
Issued: August 27, 2024
Inventor(s): Trugman; Joel M. et al.
Assignee(s): Allergan Pharmaceuticals International Limited (Dublin, IE)The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors.
Patent expiration dates:
- December 22, 2041✓
- December 22, 2041
-
Treatment of migraine
Patent 12,168,004
Issued: December 17, 2024
Inventor(s): Johnson; Mary Ann et al.
Assignee(s): Merck Sharp & Dohme LLC (Rahway, NJ)The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors.
Patent expiration dates:
- January 30, 2035✓
- January 30, 2035
-
Treatment of migraine
Patent 12,194,030
Issued: January 14, 2025
Inventor(s): Trugman; Joel M. et al.
Assignee(s): Allergan Pharmaceuticals International Limited (Dublin, IE)The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors.
Patent expiration dates:
- December 22, 2041✓
- December 22, 2041✓
- December 22, 2041
-
Treatment of migraine
Patent 12,220,408
Issued: February 11, 2025
Inventor(s): Johnson; Mary Ann et al.
Assignee(s): Merck Sharp & Dohme LLC (Rahway, NJ)The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors.
Patent expiration dates:
- January 30, 2035✓
- January 30, 2035
-
Piperidinone carboxamide azaindane CGRP receptor antagonists
Patent 8,754,096
Issued: June 17, 2014
Inventor(s): Bell Ian M. & Fraley Mark E. & Gallicchio Steven N. & Ginnetti Anthony & Mitchell Helen J. & Paone Daniel V. & Staas Donnette D. & Stevenson Heather E. & Wang Cheng & Zartman C. Blair
Assignee(s): Merck Sharp & Dohme Corp.The present invention is directed to piperidinone carboxamide azaindane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
Patent expiration dates:
- July 19, 2032✓✓✓
- July 19, 2032
-
Piperidinone carboxamide azaindane CGRP receptor antagonists
Patent 8,912,210
Issued: December 16, 2014
Inventor(s): Bell Ian M. & Fraley Mark E. & Gallicchio Steven N. & Ginnetti Anthony & Mitchell Helen J. & Paone Daniel V. & Staas Donnette D. & Wang Cheng & Zartman C. Blair
Assignee(s): Merck Sharp & Dohme Corp.The present invention is directed to piperidinone carboxamide azaindane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
Patent expiration dates:
- December 23, 2033✓✓
- December 23, 2033
-
Piperidinone carboxamide azaindane CGRP receptor antagonists
Patent 9,499,545
Issued: November 22, 2016
Inventor(s): Bell Ian M. & Fraley Mark E. & Gallicchio Steven N. & Ginnetti Anthony & Mitchell Helen J. & Paone Daniel V. & Staas Donnette D. & Wang Cheng & Zartman C. Blair
Assignee(s): Merck Sharp & Dohme Corp.The present invention is directed to piperidinone carboxamide azaindane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
Patent expiration dates:
- November 10, 2031✓✓✓
- November 10, 2031
-
Piperidinone carboxamide azaindane CGRP receptor antagonists
Patent 9,833,448
Issued: December 5, 2017
Inventor(s): Bell Ian M. & Fraley Mark E. & Gallicchio Steven N. & Ginnetti Anthony & Mitchell Helen J. & Paone Daniel V. & Staas Donnette D. & Wang Cheng & Zartman C. Blair
Assignee(s): Merck Sharp & Dohme Corp.The present invention is directed to piperidinone carboxamide azaindane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
Patent expiration dates:
- November 10, 2031✓
- November 10, 2031
More about Ubrelvy (ubrogepant)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (264)
- Drug images
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Support group
- FDA approval history
- Drug class: CGRP inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
